Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified

Abiomed

(

ABMD

) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Abiomed as such a stock due to the following factors:

  • ABMD has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $29.0 million.
  • ABMD has traded 77,141 shares today.
  • ABMD is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in ABMD with the Ticky from Trade-Ideas. See the FREE profile for ABMD NOW at Trade-Ideas

More details on ABMD:

ABIOMED, Inc. provides medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. ABMD has a PE ratio of 138.9. Currently there are 4 analysts that rate Abiomed a buy, 1 analyst rates it a sell, and 4 rate it a hold.

The average volume for Abiomed has been 465,400 shares per day over the past 30 days. Abiomed has a market cap of $2.5 billion and is part of the health care sector and health services industry. The stock has a beta of 1.47 and a short float of 14.4% with 8.59 days to cover. Shares are up 57.6% year-to-date as of the close of trading on Friday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Abiomed as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and compelling growth in net income. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value.

Highlights from the ratings report include:

  • The revenue growth greatly exceeded the industry average of 1.0%. Since the same quarter one year prior, revenues rose by 34.2%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • ABMD has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 4.52, which clearly demonstrates the ability to cover short-term cash needs.
  • The gross profit margin for ABIOMED INC is currently very high, coming in at 85.10%. It has increased from the same quarter the previous year. Along with this, the net profit margin of 20.45% is above that of the industry average.
  • Net operating cash flow has significantly increased by 79.01% to $15.13 million when compared to the same quarter last year. In addition, ABIOMED INC has also vastly surpassed the industry average cash flow growth rate of -7.27%.
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 188.7% when compared to the same quarter one year prior, rising from $4.39 million to $12.68 million.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null